Navigation Links
StemCor Systems Receives CE Mark for MarrowMiner(TM) System for Bone Marrow Collection
Date:9/10/2008

Receipt of CE Mark Clears the Way for Commercialization in the European

Union

MENLO PARK, Calif., Sept. 10 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing systems for Enabling Regenerative Medicine(TM), announced today that the Company has received the CE (Conformite European) Mark for its MarrowMiner System. The MarrowMiner System is a minimally invasive device used to harvest adult stem cells from the ilium (pelvis), and represents next-generation technology for use in bone marrow transplants, for accelerating bone healing in spinal fusions and other orthopedic procedures, and an expanding array of clinical applications utilizing bone marrow-derived cells. The CE Mark indicates that the product complies with the appropriate quality and safety standards to be commercialized in the EU, and furthers StemCor's goal of becoming a global company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO)

"We are excited that this regulatory authorization gives us the ability to commercialize StemCor Systems' technology in the European Union. The use of adult-derived stems cells is expanding rapidly, especially in spine fusion and other orthopedic procedures. We are pleased to be able to offer this novel device to physicians outside of the US, whereby bone marrow can be harvested in a more facile and relatively atraumatic way compared to traditional methods," said Vartan Ghazarossian, Ph.D., President and CEO of StemCor Systems.

About the MarrowMiner

The proprietary MarrowMiner System is designed to rapidly and easily harvest bone marrow in a minimally invasive manner, in the outpatient setting, and without general anesthesia. The System consists of an access guide, a powered handle that drives a flexible atraumatic shaft through which marrow is aspirated, and an integrated marrow collection container. The MarrowMiner shaft gains access to the bone marrow cavity through the access guide to allow the removal of bone marrow through a single entry site. This is in contrast to the current practice of bone marrow aspiration through the insertion of a needle into multiple sites in the iliac crest of the hip, which usually requires general anesthesia, an operating room, and multiple clinical personnel. Preclinical and recent clinical studies demonstrated the ability of the MarrowMiner to safely harvest marrow with significantly higher stem cell activity than is contained in standard needle aspirates.

Contact: Vartan Ghazarossian, PhD

President and CEO

StemCor Systems, Inc.

650-321-6884

Vartan@StemCorSystems.com


'/>"/>
SOURCE StemCor Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
9. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
10. PLC Systems Reports Fourth Quarter 2007 Results
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 6.35% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... Atlanta, GA (PRWEB) , ... April 25, 2017 , ... ... to their neck and back pain with a reputable physician in their area, announces ... The CRM protects patient information for patients who are looking for reputable physicians to ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... predictive analytics to its patient care management module. Using this new feature, sleep ... patient has been initiated on continuous positive airway pressure (CPAP), oral, or other ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, ... development and joint health in horses at the immunologic level. , The scientifically-developed ...
Breaking Medicine News(10 mins):